Welcome to EQUITY DEVELOPMENT

The UK's longest established regulated provider of sponsored equity research.

We launched EQUITY DEVELOPMENT in 1997 becoming the first ever  regulated provider of Sponsored Equity Research in the UK.

Our research teams are made up of expert analysts with deep understanding & experience in their sectors.  Our research is distributed to all relevant investment classes & commentators. (at no cost to the reader).

We have made our name by specialising in those companies who are not receiving the attention that they merit, using detailed commentary, appropriate valuation metrics and regular publications to help eradicate undervaluation in the medium term.

 

FREE REGISTRATION

Sign up today and access the very latest company research

LOG IN

For access to all company research please

Cozart

Cozart plc develops, manufactures and markets immunodiagnostic and other in-vitro tests for the detection of drugs of abuse for both on-site and laboratory-based sample  analysis from biological specimens that include saliva, urine, blood, and hair.

Philips agreement is another major milestone

  • Philips also exercises option to increase holding
  • Fair value per share kept at 47p

Publication Date:
June 28 2007

Home Office contract

Perfect fit…or obvious fit           

Cozart’s new financial year has started in earnest with another significant contract from the Home Office following a OJEC (Official Journal of the European Communities) competitive tendering process. This contract further strengthens the existing relationship between the two organisations and considerably enhances Cozart’s position in the oral fluid drug of abuse testing market.

Publication Date:
June 6 2007

Acquisition a perfect fit

  • Cozart acquired Nemesis Scientific
  • Specialists in workplace drug and alcohol market
  • Prior experience working together will aid swift integration

Publication Date:
March 8 2007

Cozart passes the test

  • Strong results : positive pbt and EPS
  • Revenues more than 100% higher than comparable period 2005/06
  • Healthy cash balance
  • Good progress on joint development projects
  • Fair value seen at 46p/share

Publication Date:
January 25 2007

Cozart; profitable and growing

  • Cozart now profitable again
  • Strong increase in RapiScan sales
  • Transforming acquisitions increase products and reach
  • Fair value 39p vs current 31.5p

Publication Date:
August 31 2006